子宫内膜
体外受精
多囊卵巢
胚胎移植
辅助生殖技术
生殖医学
妇科
不育
生物
医学
内分泌学
生殖技术
男科
胚胎
怀孕
胚胎发生
糖尿病
细胞生物学
胰岛素抵抗
遗传学
作者
Xiaolin Wu,Lingling Huang,Lei Liang,Ping Li
出处
期刊:Chin J Reprod Contracep
日期:2020-03-06
卷期号:40 (03): 241-245
标识
DOI:10.3760/cma.j.cn101441-20190315-00099
摘要
In order to improve the outcome of in vitro fertilization-embryo transfer (IVF-ET) treatment, recombinant human growth hormone (rhGH) has been widely used in assisted reproductive technology (ART), and has obvious improvement in patients with ovarian dysfunc-tion, such as diminished ovarian reserve (DOR), poor ovarian response (POR), polycystic ovary syndrome (PCOS), and abnormal endometrium patients such as repeated implantation failed (RIF), thin endometrium and intrauterine adhesions (IUA). But there is no unified standard about the target patients and application protocol of rhGH. This paper summarizes the mechanism and usage of rhGH in the above patients.
Key words:
Fertilization in vitro; Embryo transfer; Reproductive techniques, assisted; Recombinant human growth hormone; Ovarian dysfunction; Abnormal endometrium
科研通智能强力驱动
Strongly Powered by AbleSci AI